Evidence map›Paper›PMID 36037249›Full record

ReviewMolecular pharmaceutics2022

New Development in Understanding Drug-Polymer Interactions in Pharmaceutical Amorphous Solid Dispersions from Solid-State Nuclear Magnetic Resonance.

Andrea Pugliese, Michael Tobyn, Lucy E Hawarden, Anuji Abraham, Frédéric Blanc

Open access · hybridAbstract readReview
In one paragraph

Review in Molecular pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Panobinostat-Loaded Albumin Nanoparticles for the Treatment of Pancreatic Cancer.Journal of drug delivery science and technology · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Andrea PuglieseDepartment of Chemistry, University of Liverpool, Liverpool L69 7ZD, United Kingdom.ORCID 0000-0001-7328-0670
Michael TobynDrug Product Development, Bristol-Myers Squibb, Moreton CH46 1QW, United Kingdom.
Lucy E HawardenDrug Product Development, Bristol-Myers Squibb, Moreton CH46 1QW, United Kingdom.
Anuji AbrahamDrug Product Development, Bristol-Myers Squibb, New Brunswick, New Jersey 08903, United States.
Frédéric BlancDepartment of Chemistry, University of Liverpool, Liverpool L69 7ZD, United Kingdom.ORCID 0000-0001-9171-1454
Bristol-Myers Squibb (United Kingdom) · GBUniversity of Liverpool · GBBristol-Myers Squibb (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmaceutical amorphous solid dispersions (ASDs) represent a widely used technology to increase the bioavailability of active pharmaceutical ingredients (APIs). ASDs are based on an amorphous API dispersed in a polymer, and their stability is driven by the presence of strong intermolecular interactions between these two species (e.g., hydrogen bond, electrostatic interactions, etc.). The understanding of these interactions at the atomic level is therefore crucial, and solid-state nuclear magnetic resonance (NMR) has demonstrated itself as a very powerful technique for probing API-polymer interactions. Other reviews have also reported exciting approaches to study the structures and dynamic properties of ASDs and largely focused on the study of API-polymer miscibility and on the identification of API-polymer interactions. Considering the increased use of NMR in the field, the aim of this Review is to specifically highlight recent experimental strategies used to identify API-polymer interactions and report promising recent examples using one-dimensional (1D) and two-dimensional (2D) experiments by exploiting the following emerging approaches of very-high magnetic field and ultrafast magic angle spinning (MAS). A range of different ASDs spanning APIs and polymers with varied structural motifs is targeted to illustrate new ways to understand the mechanism of stability of ASDs to enable the design of new dispersions.

Indexed as

PolymersBiological AvailabilityDrug CompoundingHydrogen BondingMagnetic Resonance SpectroscopyPharmaceutical PreparationsSolubilityPharmaceutical PreparationsPolymersAmorphous solid dispersions (ASDs)API−polymer interactionsASD stabilityhot-melt extrusions (HMEs)solid state nuclear magnetic resonance (NMR)spray-drying (SD)

Identifiers

PMID36037249
PMCPMC9644399
OpenAlexW4293469984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.